06.02.2024
Egnach, February 6, 2024 – Since August 2023, demand for the tinnitus therapy device tinniwell has been increasing by an average of 10% per month. The COVID wave, which began in the summer of 2023, is considered to be the cause. The flattening of the waves described by experts at the beginning of the pandemic cannot be observed in any way when it comes to tinnitus. On the contrary, the number of patients with the Long Covid symptom tinnitus is increasing exorbitantly. This is now increasingly affecting more and more people who have never had to deal with tinnitus before. In previous COVID waves, the majority only affected patients who already suffered from tinnitus before the infection.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668